Your browser doesn't support javascript.
loading
How mRNA therapeutics are entering the monoclonal antibody field.
Van Hoecke, Lien; Roose, Kenny.
Affiliation
  • Van Hoecke L; VIB Center for Medical Biotechnology, VIB, Ghent, Belgium. Lien.vanhoecke@vib-ugent.be.
  • Roose K; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. Lien.vanhoecke@vib-ugent.be.
J Transl Med ; 17(1): 54, 2019 02 22.
Article in En | MEDLINE | ID: mdl-30795778
In 1975, Milstein and Köhler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies have entered almost every branch of biomedical research. Antibodies are now used as frontline therapeutics in highly divergent indications, ranging from autoimmune disease over allergic asthma to cancer. Wider accessibility and implementation of antibody-based therapeutics is however hindered by manufacturing challenges and high development costs inherent to protein-based drugs. For these reasons, alternative ways are being pursued to produce and deliver antibodies more cost-effectively without hampering safety. Over the past decade, messenger RNA (mRNA) based drugs have emerged as a highly appealing new class of biologics that can be used to encode any protein of interest directly in vivo. Whereas current clinical efforts to use mRNA as a drug are mainly situated at the level of prophylactic and therapeutic vaccination, three recent preclinical studies have addressed the feasibility of using mRNA to encode therapeutic antibodies directly in vivo. Here, we highlight the potential of mRNA-based approaches to solve several of the issues associated with antibodies produced and delivered in protein format. Nonetheless, we also identify key hurdles that mRNA-based approaches still need to take to fulfill this potential and ultimately replace the current protein antibody format.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Messenger / Antibodies, Monoclonal Limits: Animals / Humans Language: En Journal: J Transl Med Year: 2019 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Messenger / Antibodies, Monoclonal Limits: Animals / Humans Language: En Journal: J Transl Med Year: 2019 Document type: Article Affiliation country: Country of publication: